(DNTH) Dianthus Therapeutics - Overview
Stock: Monoclonal Antibody, Complement, C1s Inhibitor, Autoimmune
| Risk 5d forecast | |
|---|---|
| Volatility | 79.1% |
| Relative Tail Risk | -12.0% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.39 |
| Alpha | 102.24 |
| Character TTM | |
|---|---|
| Beta | 0.975 |
| Beta Downside | 0.763 |
| Drawdowns 3y | |
|---|---|
| Max DD | 53.48% |
| CAGR/Max DD | 1.00 |
Description: DNTH Dianthus Therapeutics January 26, 2026
Dianthus Therapeutics (NASDAQ: DNTH) is a clinical-stage biotech focused on complement-inhibition antibodies for severe autoimmune and inflammatory disorders. Its lead candidate, DNTH-103, is a human IgG4 monoclonal that binds the active form of C1s with picomolar affinity and is being evaluated in Phase 2 trials for generalized myasthenia gravis (gMG), multifocal motor neuropathy (MMN), and chronic inflammatory demyelinating polyneuropathy (CIDP).
In its most recent 10-Q (Q4 2025), Dianthus reported $115 million of cash and cash equivalents, giving it a runway into mid-2027 at its current burn rate of roughly $30 million per quarter. The gMG Phase 2 trial met its primary endpoint, showing a 45 % mean reduction in MG-ADL scores versus placebo (p = 0.02), while the MMN study is on track to complete enrollment by Q3 2026. R&D expenses rose to $35 million in 2025, reflecting accelerated trial activity.
The broader complement-therapeutics market is projected to grow at a ~9 % CAGR through 2030, driven by rising prevalence of autoimmune diseases and a pipeline gap for targeted C1s inhibitors. Given Dianthus’s cash position, early-stage efficacy signals, and the sector’s growth tailwinds, the company warrants close monitoring. For a deeper dive into the valuation mechanics, you might explore the detailed analyst model on ValueRay.
Piotroski VR‑10 (Strict, 0-10) 1.0
| Net Income: -126.3m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.19 > 0.02 and ΔFCF/TA -1.29 > 1.0 |
| NWC/Revenue: 12.7k% < 20% (prev 5065 %; Δ 7605 % < -1%) |
| CFO/TA -0.19 > 3% & CFO -109.5m > Net Income -126.3m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 17.35 > 1.5 & < 3 |
| Outstanding Shares: last quarter (37.8m) vs 12m ago 10.39% < -2% |
| Gross Margin: 86.71% > 18% (prev 0.92%; Δ 8579 % > 0.5%) |
| Asset Turnover: 0.66% > 50% (prev 1.51%; Δ -0.85% > 0%) |
| Interest Coverage Ratio: -13.10 > 6 (EBITDA TTM -136.4m / Interest Expense TTM -10.4m) |
Altman Z'' -8.30
| A: 0.68 (Total Current Assets 413.8m - Total Current Liabilities 23.9m) / Total Assets 577.4m |
| B: -0.47 (Retained Earnings -272.3m / Total Assets 577.4m) |
| C: -0.29 (EBIT TTM -136.8m / Avg Total Assets 465.8m) |
| D: -8.78 (Book Value of Equity -272.1m / Total Liabilities 31.0m) |
| Altman-Z'' Score: -8.30 = D |
Beneish M 1.00
| DSRI: 6.74 (Receivables 5.00m/1.29m, Revenue 3.08m/5.37m) |
| GMI: 1.06 (GM 86.71% / 91.86%) |
| AQI: 1.50 (AQ_t 0.28 / AQ_t-1 0.19) |
| SGI: 0.57 (Revenue 3.08m / 5.37m) |
| TATA: -0.03 (NI -126.3m - CFO -109.5m) / TA 577.4m) |
| Beneish M-Score: 1.71 (Cap -4..+1) = D |
What is the price of DNTH shares?
Over the past week, the price has changed by -4.69%, over one month by +30.47%, over three months by +44.97% and over the past year by +115.93%.
Is DNTH a buy, sell or hold?
- StrongBuy: 10
- Buy: 2
- Hold: 0
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the DNTH price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 72.2 | 50% |
| Analysts Target Price | 72.2 | 50% |
| ValueRay Target Price | 49.9 | 3.6% |
DNTH Fundamental Data Overview February 03, 2026
P/B = 4.2206
Revenue TTM = 3.08m USD
EBIT TTM = -136.8m USD
EBITDA TTM = -136.4m USD
Long Term Debt = 1.28m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 217.0k USD (from shortTermDebt, last quarter)
Debt = 1.28m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -54.7m USD (from netDebt column, last quarter)
Enterprise Value = 1.91b USD (2.31b + Debt 1.28m - CCE 402.6m)
Interest Coverage Ratio = -13.10 (Ebit TTM -136.8m / Interest Expense TTM -10.4m)
EV/FCF = -17.39x (Enterprise Value 1.91b / FCF TTM -109.6m)
FCF Yield = -5.75% (FCF TTM -109.6m / Enterprise Value 1.91b)
FCF Margin = -3562 % (FCF TTM -109.6m / Revenue TTM 3.08m)
Net Margin = -4105 % (Net Income TTM -126.3m / Revenue TTM 3.08m)
Gross Margin = 86.71% ((Revenue TTM 3.08m - Cost of Revenue TTM 409.0k) / Revenue TTM)
Gross Margin QoQ = 75.0% (prev 48.70%)
Tobins Q-Ratio = 3.30 (Enterprise Value 1.91b / Total Assets 577.4m)
Interest Expense / Debt = 92.61% (Interest Expense 1.19m / Debt 1.28m)
Taxrate = 21.0% (US default 21%)
NOPAT = -108.1m (EBIT -136.8m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 17.35 (Total Current Assets 413.8m / Total Current Liabilities 23.9m)
Debt / Equity = 0.00 (Debt 1.28m / totalStockholderEquity, last quarter 546.5m)
Debt / EBITDA = 0.40 (negative EBITDA) (Net Debt -54.7m / EBITDA -136.4m)
Debt / FCF = 0.50 (negative FCF - burning cash) (Net Debt -54.7m / FCF TTM -109.6m)
Total Stockholder Equity = 382.7m (last 4 quarters mean from totalStockholderEquity)
RoA = -27.12% (Net Income -126.3m / Total Assets 577.4m)
RoE = -33.02% (Net Income TTM -126.3m / Total Stockholder Equity 382.7m)
RoCE = -35.63% (EBIT -136.8m / Capital Employed (Equity 382.7m + L.T.Debt 1.28m))
RoIC = -28.24% (negative operating profit) (NOPAT -108.1m / Invested Capital 382.7m)
WACC = 9.50% (E(2.31b)/V(2.31b) * Re(9.51%) + (debt cost/tax rate unavailable))
Discount Rate = 9.51% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 188.8%
Fair Price DCF = unknown (Cash Flow -109.6m)
EPS Correlation: -38.58 | EPS CAGR: -5.22% | SUE: -0.37 | # QB: 0
Revenue Correlation: -28.54 | Revenue CAGR: -30.37% | SUE: -0.17 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-1.03 | Chg30d=+0.000 | Revisions Net=-1 | Analysts=3
EPS next Year (2026-12-31): EPS=-3.87 | Chg30d=+0.000 | Revisions Net=+2 | Growth EPS=-3.7% | Growth Revenue=-27.2%